Jump to content

Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Botanical

or Opioid

or [[:Category:Hormone_replacement_therapy|Hormone replacement therapy]]

Use the filters below to narrow your results.

Codeine (2)

Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · None (2) · Contains LSA (2) · Contains mescaline (2)

Other values:

None (51) · Mild to moderate pain; cough suppression (low-dose). (1) · '"`UNIQ--vote-000003B5-QINU`"', '"`UNIQ--vote-000003B6-QINU`"', '"`UNIQ--vote-000003B7-QINU`"', '"`UNIQ--vote-000003B8-QINU`"', '"`UNIQ--vote-000003B9-QINU`"' (1) · '"`UNIQ--vote-00000722-QINU`"', '"`UNIQ--vote-00000723-QINU`"', '"`UNIQ--vote-00000724-QINU`"', '"`UNIQ--vote-00000725-QINU`"' (1)

None (51) · Adult: 15–60 mg every 4 hours as needed. (1) · HRT cyclic: 200 mg PO HS days 1-12 of each month; continuous: 100 mg PO daily; ART luteal support 100 mg vaginal TID or 90 mg gel daily (1) · Oral 1-2 mg daily; transdermal patch 0.025-0.05 mg/d twice weekly; transdermal gel 0.5-1 g/d; vaginal 10 mcg tablet twice weekly for GSM. Always combine with a progestogen in patients with an intact uterus. (1)

None (51) · Oral 0.5, 1, 2 mg tablets; transdermal patches (twice-weekly and once-weekly); 0.06% gel; 1.53 mg/spray topical; vaginal ring (Estring); vaginal tablet (Vagifem/Yuvafem); vaginal cream (1) · Oral 100, 200 mg capsules (peanut oil; check allergy); 100 mg vaginal insert (Endometrin); 4%, 8% vaginal gel (Crinone); IM 50 mg/mL (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (51) · 360 mg/day (1) · Indication-dependent; 200-400 mg/d oral typical (1) · Indication-specific; lowest effective dose for shortest duration is the WHI-era standard (1)

None (51) · cypionate) (1) · IM (estradiol valerate (1) · intramuscular (1) · Oral (2) · PO (only formulation marketed in the US). (1) · transdermal (1) · vaginal (2)

None (51) · 30–60 min (PO) (1) · Sedation/dizziness within hours of oral dose; endometrial effects over days (1) · Vasomotor relief 2-4 weeks; bone density gains over months (1)

None (51) · 4–6 hours (1) · Oral: 8-12 hours; vaginal: 24+ hours; IM: days (1) · Route- and formulation-dependent (1)

None (51) · 2.5–3 hours (1) · ~13-20 hours (oral); transdermal pharmacokinetics buffer the peaks/troughs of oral dosing'"`UNIQ--ref-000003BA-QINU`"' (1) · ~5-20 hours (oral micronized; highly variable)'"`UNIQ--ref-00000726-QINU`"' (1)

None (51) · Oral ~5% (extensive first-pass to estrone and conjugates); transdermal bypasses first-pass, giving more physiologic estradiol:estrone ratio'"`UNIQ--ref-000003BB-QINU`"' (1) · Oral: very low (extensive first-pass); micronization improves uptake somewhat. Vaginal: high local effect with lower systemic levels (first-uterine-pass concentration)'"`UNIQ--ref-00000727-QINU`"' (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (52) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Contraindicated in pregnancy (use is not appropriate during gestation; class label X). Lactation considerations vary by indication.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (51) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

Showing below up to 57 results in range #1 to #57.

7

A

B

C

D

E

Estradiol

Ethylmorphine

F

Fentanyl

H

I

Iboga

K

L

Levorphanol

M

N

Nalbuphine

O

P

R

Remifentanil

S

T

U

U-47700

Y

Yopo

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"